{"organizations": [], "uuid": "b011492477b74cbe1e336f0678d66ceaab28a6b8", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/7", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/04/30/globe-newswire-chimerix-to-announce-first-quarter-2018-financial-results-on-may-7-2018.html", "country": "US", "domain_rank": 767, "title": "Chimerix to Announce First Quarter 2018 Financial Results on May 7, 2018", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-30T16:00:00.000+03:00", "replies_count": 0, "uuid": "b011492477b74cbe1e336f0678d66ceaab28a6b8"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/04/30/globe-newswire-chimerix-to-announce-first-quarter-2018-financial-results-on-may-7-2018.html", "ord_in_thread": 0, "title": "Chimerix to Announce First Quarter 2018 Financial Results on May 7, 2018", "locations": [], "entities": {"persons": [{"name": "chimerix", "sentiment": "none"}, {"name": "chimerix chimerix", "sentiment": "none"}], "locations": [{"name": "durham", "sentiment": "none"}, {"name": "n.c.", "sentiment": "none"}], "organizations": [{"name": "company", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "DURHAM, N.C., April 30, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals for the growing population of immunocompromised patients, today announced that it will host a live conference call and audio webcast on Monday, May 7, 2018 at 8:30 a.m. ET to report financial results for the first quarter ended March 31, 2018, and to provide a business overview.\nTo access the live conference call, please dial (877) 354-4056 (domestic) or (678) 809-1043 (international) at least five minutes prior to the start time and refer to conference ID 6173279. A live audio webcast of the call and accompanying slide presentation will also be available on the Investors’ section of the Company's website, www.chimerix.com . An archived webcast and accompanying slides will be available on the Chimerix website approximately two hours after the event.\nAbout Chimerix\nChimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients. Chimerix's proprietary lipid conjugate technology and compound library have produced brincidofovir (BCV, CMX001); CMX157, which was licensed to ContraVir Pharmaceuticals; and a new clinical candidate, CMX521, the first direct-acting antiviral specifically for the treatment and prevention of norovirus. For further information, please visit Chimerix's website, www.chimerix.com .\nCONTACT:\nInvestor Relations:\nMichelle LaSpaluto\n(919) 972-7115\nir@chimerix.com\nor\nWill O’Connor\nStern Investor Relations\nWill@sternir.com\n212-362-1200\nMedia:\nBecky Vonsiatsky\nW2O Group\nbvonsiatsky@w2ogroup.com\n413-478-2003\nSource:Chimerix, Inc.", "external_links": ["https://www.globenewswire.com/NewsRoom/AttachmentNg/9b5bc625-104d-4a8b-9efc-877699d633d4", "https://www.globenewswire.com/Tracker?data=_7xUZ9w29bEOXXGZQt4BQs38ZcqUxsLILUi8Eu5Djmf9nGq544H73Aq6YKFsxyM22s7tNlRdEOGLDyAg0hmmtA==", "https://www.globenewswire.com/Tracker?data=jbNxY0Az4UCBdLx_5zkbm5jQgcDiytmD2SaSzD6V2MCWX4a8vXTjoceDkIuJWmwyyqOucTTT4-UtGcHkKp692A==", "https://www.globenewswire.com/Tracker?data=_7xUZ9w29bEOXXGZQt4BQt_JGBYgamKKIZ9JrIe1EKVoZ9zuDJriZANlvwR3Na0LFFYceVtC2X0UXP3vsIqlucvW6huWvAf3_MwI1KtQAD26OPVNkV7ctpfbHqe7wnJ39detA7tY2DNJmLYHbKsK8070CTPUncF4J2WpIRN4mt1axqj-33gvb6y16cclsKN4-MvOcSnRYO-Yij_oSrdK7hGycNzuYbi0G1L9eQGAnJs=", "https://www.globenewswire.com/Tracker?data=bchZEKjziW2vkZm5Fa6ro9toUx4iSvqPpUY2r03-Jp_WP-QC8U3GlU9qJjLEa4iIYXB8UhBEcQW6ZqL9JVUWHPFbve0g-JsuUlScDGvhW1-Bzfz7mnJnJ2ESDC7wTgs3Tt-wFFkWbEUiCJsiKXkPzqwLPbtB5oL6NPb6VB_FBhPs_5NuBgBT_s9S4OviC5RJrTjRvSF19jPTpglXj5LQvw==", "https://www.globenewswire.com/Tracker?data=4WyMknaIyBSjVvuj6b4p4KjVKg0KDqgjhfr7xCslgNr88RKsbxXdY0W2o9FuXYoGtDyD2DMpSe5nWfLOcSYR9A==", "https://www.globenewswire.com/Tracker?data=nPJvBz6wuPAklOUnG8J-UIfxaLCOIXTeBcc5Czx81epWJLFjPUbQcB35e155OG5Wxb1firOPk6ogmi8m1Tj75reuTZV2gSP23kkFllUSNJo=", "https://www.globenewswire.com/Tracker?data=YAtHi4P-TJJhcAhw1NdzSUgYFuxehccu9LbNDZPZmQkDToRA30P59dfDWPFnHqg6V4Flfp6Sj2rPMZboVyvsZA=="], "published": "2018-04-30T16:00:00.000+03:00", "crawled": "2018-04-30T18:15:49.001+03:00", "highlightTitle": ""}